Genomic Analysis of Non- NF2 Meningiomas Rev KLF4 , AKT1 , and SMO

Science

339, 1077-1080

DOI: 10.1126/science.1233009

Citation Report

#	Article	IF	Citations
1	Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncology, The, 2013, 14, e370-e379.	5.1	167
2	Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nature Genetics, 2013, 45, 1050-1054.	9.4	519
3	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathologica, 2013, 125, 351-358.	3.9	208
4	Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nature Medicine, 2013, 19, 1410-1422.	15.2	489
5	AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathologica, 2013, 126, 757-762.	3.9	88
6	The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nature Reviews Cancer, 2013, 13, 412-424.	12.8	462
7	Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas. Journal of Neuro-Oncology, 2013, 113, 385-396.	1.4	14
8	Akt SUMOylation Regulates Cell Proliferation and Tumorigenesis. Cancer Research, 2013, 73, 5742-5753.	0.4	109
9	<i>CCM3</i> Mutations Are Associated with Early-Onset Cerebral Hemorrhage and Multiple Meningiomas. Molecular Syndromology, 2013, 4, 165-172.	0.3	74
10	Molecular insights into brain tumors. Current Opinion in Neurology, 2013, 26, 678-680.	1.8	1
11	Next-generation molecular genetics of brain tumours. Current Opinion in Neurology, 2013, 26, 681-687.	1.8	15
12	High-grade meningiomas. Current Opinion in Neurology, 2013, 26, 708-715.	1.8	14
13	Radiation Treatment for WHO Grade II and III Meningiomas. Frontiers in Oncology, 2013, 3, 227.	1.3	71
14	Inversion-mediated gene fusions involving NAB2-STAT6 in an unusual malignant meningioma. British Journal of Cancer, 2013, 109, 1051-1055.	2.9	10
15	The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro-Oncology, 2013, 15, 1479-1490.	0.6	72
16	Inflammation Triggered by Traumatic Brain Injury May Continue to Harm the Brain for a Lifetime. Neurosurgery, 2013, 72, N19-N20.	0.6	5
17	Genomic Analysis of Non-Neurofibromatosis Type 2 Meningiomas. Neurosurgery, 2013, 72, N18-N19.	0.6	0
18	Identification of Novel Therapeutic Targets Through Genomic Analysis of Meningiomas. Neurosurgery, 2013, 73, N22-N24.	0.6	1

#	Article	IF	Citations
19	Association between Inflammatory Infiltrates and Isolated Monosomy 22/del(22q) in Meningiomas. PLoS ONE, 2013, 8, e74798.	1.1	31
20	Targeting hedgehog signaling in cancer: research and clinical developments. OncoTargets and Therapy, 2013, 6, 1425.	1.0	59
21	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget, 2014, 5, 10596-10606.	0.8	65
22	Personalized Cancer Therapy. , 2014, , 671-824.		1
23	Smoothened gene alterations in keratocystic odontogenic tumors. Head & Face Medicine, 2014, 10, 36.	0.8	19
24	Brain Malformations Associated With Knobloch Syndromeâ€"Review of Literature, Expanding Clinical Spectrum, and Identification of Novel Mutations. Pediatric Neurology, 2014, 51, 806-813.e8.	1.0	43
25	High Incidence of Activating <scp>TERT</scp> Promoter Mutations in Meningiomas Undergoing Malignant Progression. Brain Pathology, 2014, 24, 184-189.	2.1	209
26	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathologica Communications, 2014, 2, 167.	2.4	65
27	Activating FGFR2â€"RASâ€"BRAF Mutations in Ameloblastoma. Clinical Cancer Research, 2014, 20, 5517-5526.	3.2	213
28	Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations. Journal of Hepatology, 2014, 61, 1178-1183.	1.8	48
29	Follicle-stimulating hormone receptor (FSHR) alternative skipping of exon 2 or 3 affects ovarian response to FSH. Molecular Human Reproduction, 2014, 20, 630-643.	1.3	25
30	A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. Journal of Neuro-Oncology, 2014, 117, 93-101.	1.4	93
31	Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 473-485.	1.4	46
32	Germline <scp>SMARCE1</scp> mutations predispose to both spinal and cranial clear cell meningiomas. Journal of Pathology, 2014, 234, 436-440.	2.1	108
33	Update from the 2013 international neurofibromatosis conference. American Journal of Medical Genetics, Part A, 2014, 164, 2969-2978.	0.7	17
34	ERK5/KLF4 signaling as a common mediator of the neuroprotective effects of both nerve growth factor and hydrogen peroxide preconditioning. Age, 2014, 36, 9685.	3.0	37
35	Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nature Genetics, 2014, 46, 722-725.	9.4	273
37	Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2014, 32, 129-160.	0.8	74

#	Article	IF	Citations
38	Global expression profile in low grade meningiomas and schwannomas shows upregulation of PDGFD, CDH1 and SLIT2 compared to their healthy tissue. Oncology Reports, 2014, 32, 2327-2334.	1.2	18
39	Pathology and Molecular Genetics of Meningioma: Recent Advances. Neurologia Medico-Chirurgica, 2015, 55, 14-27.	1.0	54
40	Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. Biomarkers in Cancer, 2015, 7s2, BIC.S29329.	3.6	54
41	Brain Tumor Clinical Trials. Neurosurgery, 2015, 62, 141-145.	0.6	0
42	Immunohistochemical and molecular analysis of PI3K/<scp>AKT</scp>/m<scp>TOR</scp> pathway in esophageal carcinoma. Apmis, 2015, 123, 639-647.	0.9	18
43	Skull Base Meningiomas. Neurosurgery, 2015, 62, 30-49.	0.6	13
44	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget, 2015, 6, 4704-4716.	0.8	127
45	Distinguishing grade I meningioma from higher grade meningiomas without biopsy. Oncotarget, 2015, 6, 38421-38428.	0.8	17
46	Biology and Clinical Management Challenges in Meningioma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e106-e115.	1.8	26
47	Genetic/molecular alterations of meningiomas and the signaling pathways targeted. Oncotarget, 2015, 6, 10671-10688.	0.8	58
48	PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination withNf2andCdkn2abloss. Oncotarget, 2015, 6, 32713-32722.	0.8	35
49	The protein expression profile of meningioma cells is associated with distinct cytogenetic tumour subgroups. Neuropathology and Applied Neurobiology, 2015, 41, 319-332.	1.8	10
50	Germline and somatic mutations in meningiomas. Cancer Genetics, 2015, 208, 107-114.	0.2	72
51	Neurosurgery concepts: Key perspectives on dendritic cell vaccines, metastatic tumor treatment, and radiosurgery. , 2015, 6, 6.		1
52	Genomic Applications in Brain Tumors. , 2015, , 321-339.		0
53	Personalized Therapy of Cancer. , 2015, , 199-381.		1
54	Endonasal Endoscopic Management of Parasellar and Cavernous Sinus Meningiomas. Neurosurgery Clinics of North America, 2015, 26, 389-401.	0.8	25
55	The cerebral cavernous malformation 3 gene is necessary for senescence induction. Aging Cell, 2015, 14, 274-283.	3.0	17

#	Article	IF	Citations
56	Smoothened Goes Molecular: New Pieces in the Hedgehog Signaling Puzzle. Journal of Biological Chemistry, 2015, 290, 3500-3507.	1.6	21
57	Hereditary Predisposition to Primary CNS Tumors. Molecular Pathology Library, 2015, , 1-22.	0.1	0
59	Cancer genomics: why rare is valuable. Journal of Molecular Medicine, 2015, 93, 369-381.	1.7	8
60	Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells. Clinical Cancer Research, 2015, 21, 505-513.	3.2	115
61	Efficacy of Hedgehog Pathway Inhibitors in Basal Cell Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 633-641.	1.9	64
62	The Hedgehog pathway: role in cell differentiation, polarity and proliferation. Archives of Toxicology, 2015, 89, 179-191.	1.9	97
63	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology, 2015, 84, 280-286.	1.5	92
64	Neuropathology Simplified. , 2015, , .		0
65	Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma. Cancer Cell, 2015, 27, 327-341.	7.7	316
66	Whole exome sequencing in a case of sporadic multiple meningioma reveals shared NF2, FAM109B, and TPRXL mutations, together with unique SMARCB1 alterations in a subset of tumor nodules. Cancer Genetics, 2015, 208, 327-332.	0.2	14
67	A 10-minute prototype assay for tissue degradation monitoring in clinical specimens. Experimental and Molecular Pathology, 2015, 99, 86-94.	0.9	3
68	Molecular typing of meningiomas by desorption electrospray ionization mass spectrometry imaging for surgical decision-making. International Journal of Mass Spectrometry, 2015, 377, 690-698.	0.7	46
69	The Genetics of Aneurysms: A Complex Pathophysiology Requiring Complex Analysis. World Neurosurgery, 2015, 83, 280-281.	0.7	2
70	World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment. British Journal of Neurosurgery, 2015, 29, 693-698.	0.4	41
71	A rare case of congenital fibrosis of extraocular muscle type 1A due to KIF21A mutation with Marcus Gunn jaw-winking phenomenon. European Journal of Paediatric Neurology, 2015, 19, 743-746.	0.7	6
72	Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations. PLoS Computational Biology, 2015, 11, e1004147.	1.5	59
73	ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genetics, 2015, 208, 345-350.	0.2	73
74	Human aging in the post-GWAS era: further insights reveal potential regulatory variants. Biogerontology, 2015, 16, 529-541.	2.0	5

#	Article	IF	Citations
75	Deficiency of the protein-tyrosine phosphatase DEP-1/PTPRJ promotes matrix metalloproteinase-9 expression in meningioma cells. Journal of Neuro-Oncology, 2015, 122, 451-459.	1.4	5
77	Antiangiogenic Treatment of Meningiomas. Current Treatment Options in Neurology, 2015, 17, 359.	0.7	5
78	Survival in patients treated for anaplastic meningioma. Journal of Neurosurgery, 2015, 123, 23-30.	0.9	74
79	Age-associated brain regions in gliomas: a volumetric analysis. Journal of Neuro-Oncology, 2015, 123, 299-306.	1.4	13
80	Regulation of the oncoprotein Smoothened by small molecules. Nature Chemical Biology, 2015, 11, 246-255.	3.9	107
81	An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. Neurosurgical Focus, 2015, 38, E3.	1.0	107
82	Textbook of Personalized Medicine. , 2015, , .		27
83	SomaticPOLEmutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology, 2015, 17, 1356-1364.	0.6	94
84	Stereotactic Radiosurgery for Intracranial Meningiomas. Neurosurgery, 2015, 76, 362-371.	0.6	22
85	A five year-old child with clear cell petro-clival meningioma: case report with clinical and histopathological long-term follow-up. Child's Nervous System, 2015, 31, 2193-2198.	0.6	14
86	Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. Journal of Clinical Oncology, 2015, 33, 4093-4098.	0.8	120
87	Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochirurgica, 2015, 157, 1741-1746.	0.9	56
88	Malignant progression to anaplastic meningioma: Neuropathology, molecular pathology, and experimental models. Experimental and Molecular Pathology, 2015, 99, 354-359.	0.9	25
90	Genetic Profiling by Singleâ€Nucleotide Polymorphismâ€Based Array Analysis Defines Three Distinct Subtypes of Orbital Meningioma. Brain Pathology, 2015, 25, 193-201.	2.1	19
91	SWI/SNF Chromatin Remodeling and Human Malignancies. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 145-171.	9.6	242
92	Atypical meningoma: current management dilemmas and prospective clinical trials. Journal of Neuro-Oncology, 2015, 121, 1-7.	1.4	39
93	Genetics of Complex Traits in Psychiatry. Biological Psychiatry, 2015, 77, 36-42.	0.7	47
94	Genomic Applications in Pathology. , 2015, , .		1

#	Article	IF	Citations
95	Critical Molecular and Genetic Markers in Primary Brain Tumors with Their Clinical Importance. , 0, , .		1
96	Proteomics Analysis of Brain Meningiomas in Pursuit of Novel Biomarkers of the Aggressive Behavior. Journal of Proteomics and Bioinformatics, 2016, 09, 53-57.	0.4	33
97	Differentially Expressed MicroRNAs in Meningiomas Grades I and II Suggest Shared Biomarkers with Malignant Tumors. Cancers, 2016, 8, 31.	1.7	23
98	Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling. Cancers, 2016, 8, 67.	1.7	38
99	Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. International Journal of Molecular Sciences, 2016, 17, 683.	1.8	29
100	Differential Cellular Responses to Hedgehog Signalling in Vertebratesâ€"What is the Role of Competence?. Journal of Developmental Biology, 2016, 4, 36.	0.9	15
101	Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications. Frontiers in Surgery, 2016, 3, 40.	0.6	70
102	Renal involvement in patients with mucolipidosis IIIalpha/beta: Causal relation or coâ€occurrence?. American Journal of Medical Genetics, Part A, 2016, 170, 1187-1195.	0.7	4
103	Activation of multiple growth factor signalling pathways is frequent in meningiomas. Neuropathology, 2016, 36, 250-261.	0.7	28
104	A novel mutation of the FAT2 gene in spinal meningioma. Oncology Letters, 2016, 12, 3393-3396.	0.8	6
105	Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics. Neurosurgical Focus, 2016, 41, E3.	1.0	16
106	World Health Organization grade II meningiomas. Acta Neurochirurgica, 2016, 158, 921-929.	0.9	19
107	Impact of 1p/19q codeletion on the diagnosis and prognosis of different grades of meningioma. British Journal of Neurosurgery, 2016, 30, 571-576.	0.4	2
108	Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system. Modern Pathology, 2016, 29, 708-716.	2.9	38
109	PIK3CA mutations in meningioma. Neuro-Oncology, 2016, 18, 603-604.	0.6	7
110	Parameters influencing local control of meningiomas treated with radiosurgery. Journal of Neuro-Oncology, 2016, 128, 357-364.	1.4	30
111	Systemic therapy for recurrent meningioma. Expert Review of Neurotherapeutics, 2016, 16, 889-901.	1.4	20
112	EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncology, The, 2016, 17, e383-e391.	5.1	627

#	Article	IF	Citations
113	Familial occurrence of brain arteriovenous malformation: a novel ACVRL1 mutation detected by whole exome sequencing. Journal of Neurosurgery, 2016, 126, 1879-1883.	0.9	16
114	Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas. Journal of Neuro-Oncology, 2016, 130, 473-484.	1.4	13
115	World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment. Neurochirurgie, 2016, 62, 203-208.	0.6	21
116	A study of prognostic factors in 45 cases of atypical meningioma. Acta Neurochirurgica, 2016, 158, 1661-1667.	0.9	42
117	Classification of human meningiomas: lights, shadows, and future perspectives. Journal of Neuroscience Research, 2016, 94, 1604-1612.	1.3	28
118	Mutations of the Sonic Hedgehog Pathway Underlie Hypothalamic Hamartoma with Gelastic Epilepsy. American Journal of Human Genetics, 2016, 99, 423-429.	2.6	59
119	Somatic AKT1 mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis. American Journal of Medical Genetics, Part A, 2016, 170, 2605-2610.	0.7	24
120	Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nature Genetics, 2016, 48, 1253-1259.	9.4	265
121	Genetic landscape of meningioma. Brain Tumor Pathology, 2016, 33, 237-247.	1.1	118
122	Genomic Landscape of Brain Tumors. , 2016, , 653-663.		0
123	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	0.6	99
125	Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression. Developmental Cell, 2016, 39, 452-465.	3.1	23
126	Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10672-10677.	3.3	42
127	Multiple Meningiomas in a Patient with Cowden Syndrome. Journal of Neurological Surgery Reports, 2016, 77, e128-e133.	0.3	7
128	Molecular, Cellular, and Genetic Determinants of Sporadic Brain Arteriovenous Malformations. Neurosurgery, 2016, 63, 37-42.	0.6	17
129	Checkpoint inhibition in meningiomas. Immunotherapy, 2016, 8, 721-731.	1.0	22
130	A Recurrent Mosaic Mutation in SMO , Encoding the Hedgehog Signal Transducer Smoothened, Is the Major Cause of Curry-Jones Syndrome. American Journal of Human Genetics, 2016, 98, 1256-1265.	2.6	70
131	WHO grade II meningioma: a retrospective study for outcome and prognostic factor assessment. Journal of Neuro-Oncology, 2016, 129, 337-345.	1.4	55

#	Article	IF	Citations
132	Brain Invasion in Meningiomas: Incidence and Correlations with Clinical Variables and Prognosis. World Neurosurgery, 2016, 93, 346-354.	0.7	69
133	Case-Based Review: meningioma. Neuro-Oncology Practice, 2016, 3, 120-134.	1.0	6
134	Genomic landscape of intracranial meningiomas. Journal of Neurosurgery, 2016, 125, 525-535.	0.9	104
135	Genomic and Epigenomic Landscape in Meningioma. Neurosurgery Clinics of North America, 2016, 27, 167-179.	0.8	31
136	A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro-Oncology, 2016, 18, 1278-1287.	0.6	25
137	World Health Organization Grade II Meningioma: A 10-Year Retrospective Study for Recurrence and Prognostic Factor Assessment. World Neurosurgery, 2016, 89, 180-186.	0.7	60
138	Oncogenic PI3K mutations are as common asAKT1andSMOmutations in meningioma. Neuro-Oncology, 2016, 18, 649-655.	0.6	221
139	Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?. Brain Tumor Pathology, 2016, 33, 191-199.	1.1	5
140	A patient with a novel homozygous missense mutation in FTO and concomitant nonsense mutation in CETP. Journal of Human Genetics, 2016, 61, 395-403.	1.1	14
141	Medical Management of Meningiomas. Neurosurgery Clinics of North America, 2016, 27, 249-260.	0.8	36
142	Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature Genetics, 2016, 48, 407-416.	9.4	730
144	Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nature Genetics, 2016, 48, 398-406.	9.4	370
145	Biomarkers Applied to Specific Tumor Types. , 2016, , 59-98.		0
146	TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377.	3.0	283
147	Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with nonâ€“skull base meningiomas. Journal of Neurosurgery, 2016, 125, 431-440.	0.9	49
148	Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro-Oncology, 2016, 18, 379-387.	0.6	101
149	Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity. Molecular and Cellular Oncology, 2016, 3, e1098791.	0.3	19
150	Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro-Oncology, 2016, 18, 863-872.	0.6	91

#	Article	IF	Citations
151	Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nature Genetics, 2016, 48, 59-66.	9.4	253
152	KLF4 regulates adult lung tumor-initiating cells and represses K-Ras-mediated lung cancer. Cell Death and Differentiation, 2016, 23, 207-215.	5.0	60
153	RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma. Molecular Neurobiology, 2017, 54, 779-787.	1.9	16
154	The new WHO 2016 classification of brain tumorsâ€"what neurosurgeons need to know. Acta Neurochirurgica, 2017, 159, 403-418.	0.9	85
155	SMOmutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro-Oncology, 2017, 19, now276.	0.6	49
156	Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells. European Journal of Cancer, 2017, 73, 9-21.	1.3	27
157	Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathologica, 2017, 133, 431-444.	3.9	155
158	Impact of Genetic Variation on Human CaMKK2 Regulation by Ca2+-Calmodulin and Multisite Phosphorylation. Scientific Reports, 2017, 7, 43264.	1.6	15
159	Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. EBioMedicine, 2017, 16, 76-86.	2.7	22
160	Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nature Communications, 2017, 8, 14433.	5.8	156
162	Genetic and epigenetic alterations in meningiomas. Clinical Neurology and Neurosurgery, 2017, 158, 119-125.	0.6	69
163	Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence. Neuro-Oncology, 2017, 19, 1088-1096.	0.6	69
164	BAP1 mutations in high-grade meningioma: implications for patient care. Neuro-Oncology, 2017, 19, 1447-1456.	0.6	125
165	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. Acta Neuropathologica, 2017, 134, 155-158.	3.9	26
166	Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. Journal of Neurosurgery, 2017, 127, 438-444.	0.9	48
167	Comparative Proteomic Profiling Using Two-Dimensional Gel Electrophoresis and Identification via LC-MS/MS Reveals Novel Protein Biomarkers to Identify Aggressive Subtypes of WHO Grade I Meningioma. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, 371-379.	0.4	10
168	Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma. Cancer Genetics, 2017, 212-213, 32-37.	0.2	19
169	The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value?. Journal of Neuro-Oncology, 2017, 133, 641-651.	1.4	84

#	Article	IF	Citations
170	Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas. Journal of Neuro-Oncology, 2017, 133, 633-639.	1.4	4
171	Sporadic pediatric meningiomas: a neuroradiological and neuropathological study of 15 cases. Journal of Neurosurgery: Pediatrics, 2017, 20, 141-148.	0.8	10
172	Genomic landscape of high-grade meningiomas. Npj Genomic Medicine, 2017, 2, .	1.7	130
173	Diagnostic challenges in meningioma. Neuro-Oncology, 2017, 19, 1588-1598.	0.6	106
174	PET imaging in patients with meningiomaâ€"report of the RANO/PET Group. Neuro-Oncology, 2017, 19, 1576-1587.	0.6	157
175	Epigenetics: a new tool for meningioma management?. Lancet Oncology, The, 2017, 18, 569-570.	5.1	8
176	Disruptions in asymmetric centrosome inheritance and WDR62-Aurora kinase B interactions in primary microcephaly. Scientific Reports, 2017, 7, 43708.	1.6	37
178	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	5.1	586
179	Genomic analysis reveals frequent TRAF7 mutations in intraneural perineuriomas. Annals of Neurology, 2017, 81, 316-321.	2.8	53
180	Personalized Medicine Through Advanced Genomics. , 2017, , 31-48.		1
182	Report of a Novel Case of Anaplastic Olfactory Groove Meningioma and Its Methylation Subtype. Journal of Neuropathology and Experimental Neurology, 2017, 76, 997-999.	0.9	0
183	The Top-100 Most-Cited Articles on Meningioma. World Neurosurgery, 2017, 107, 1025-1032.e5.	0.7	36
184	Atypical meningioma. A study on recurrence and disease-specific survival. Neurochirurgie, 2017, 63, 273-281.	0.6	42
185	Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). Genes Chromosomes and Cancer, 2017, 56, 719-729.	1.5	14
186	Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nature Communications, 2017, 8, 186.	5.8	76
187	Cellular prion protein (PrPC) in the development of Merlin-deficient tumours. Oncogene, 2017, 36, 6132-6142.	2.6	24
188	SMO mutant olfactory groove meningiomasâ€"the next in line for targeted therapy. Neuro-Oncology, 2017, 19, 305-306.	0.6	1
189	Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas. Journal of the Neurological Sciences, 2017, 380, 112-121.	0.3	24

#	Article	IF	Citations
190	KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas. Journal of Molecular Cell Biology, 2017, 9, 315-324.	1.5	39
191	Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. Journal of the National Cancer Institute, 2017, 109, 1-4.	3.0	51
192	First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation. BMC Cancer, 2017, 17, 127.	1.1	13
193	ALPK3 gene mutation in a patient with congenital cardiomyopathy and dysmorphic features. Journal of Physical Education and Sports Management, 2017, 3, a001859.	0.5	20
194	The Emerging Role of TRAF7 in Tumor Development. Journal of Cellular Physiology, 2017, 232, 1233-1238.	2.0	68
195	Optimizing gDNA extraction from fresh frozen meningioma tissue for downstream genetic analysis. Clinical Biochemistry, 2017, 50, 194-205.	0.8	2
196	<scp>SMARCE</scp>1 mutation screening in classification of clear cell meningiomas. Histopathology, 2017, 70, 814-820.	1.6	27
197	Pathology and Molecular Pathology of Brain Cancer. , 2017, , 291-311.		2
198	A description of familial clustering of meningiomas in the Utah population. Neuro-Oncology, 2017, 19, 1683-1687.	0.6	4
199	Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. Cell Communication and Signaling, 2017, 15, 34.	2.7	21
200	Whole-genome sequencing identifies new genetic alterations in meningiomas. Oncotarget, 2017, 8, 17070-17080.	0.8	17
201	Genomic profile of human meningioma cell lines. PLoS ONE, 2017, 12, e0178322.	1.1	44
202	Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive primary meningioma cell lines. Cancer Cell International, 2017, 17, 72.	1.8	21
203	Molecular Testing of Brain Tumor. Journal of Pathology and Translational Medicine, 2017, 51, 205-223.	0.4	56
204	Molecular genetics of meningiomas: Building the roadmap towards personalized therapy. Neurochirurgie, 2018, 64, 22-28.	0.6	23
205	Salvage therapy outcomes for atypical meningioma. Journal of Neuro-Oncology, 2018, 138, 425-433.	1.4	25
206	Pain correlates with germline mutation in schwannomatosis. Medicine (United States), 2018, 97, e9717.	0.4	20
207	Medical management of meningioma in the era of precision medicine. Neurosurgical Focus, 2018, 44, E3.	1.0	45

#	Article	IF	Citations
208	High-grade meningiomas: biology and implications. Neurosurgical Focus, 2018, 44, E2.	1.0	31
209	Relationship between tumor location, size, and WHO grade in meningioma. Neurosurgical Focus, 2018, 44, E4.	1.0	97
210	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica, 2018, 135, 955-963.	3.9	109
211	Brain Tumors. American Journal of Medicine, 2018, 131, 874-882.	0.6	121
212	Genomic analysis of synchronous intracranial meningiomas with different histological grades. Journal of Neuro-Oncology, 2018, 138, 41-48.	1.4	2
213	Current treatment options for meningioma. Expert Review of Neurotherapeutics, 2018, 18, 241-249.	1.4	147
214	Genotypeâ€“phenotype investigation of 35 patients from 11 unrelated families with camptodactylyâ€“arthropathyâ€“coxa varaâ€“pericarditis (<scp>CACP</scp>) syndrome. Molecular Genetics & Genomic Medicine, 2018, 6, 230-248.	0.6	15
215	Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. Scientific Reports, 2018, 8, 2098.	1.6	42
216	Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma. Annals of Oncology, 2018, 29, 537-540.	0.6	4
217	Prediction of progression in skull base meningiomas: additional benefits of apparent diffusion coefficient value. Journal of Neuro-Oncology, 2018, 138, 63-71.	1.4	17
218	Progestin-associated shift of meningioma mutational landscape. Annals of Oncology, 2018, 29, 681-686.	0.6	59
219	Recent advances in intradural spinal tumors. Neuro-Oncology, 2018, 20, 729-742.	0.6	36
220	Advances in meningioma genetics: novel therapeutic opportunities. Nature Reviews Neurology, 2018, 14, 106-115.	4.9	148
221	Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation. Cell Reports, 2018, 22, 3672-3683.	2.9	95
222	Meningiomas: Overview and New Directions in Therapy. Seminars in Neurology, 2018, 38, 112-120.	0.5	32
223	Spheno-Orbital Meningiomas: An Analysis Based on World Health Organization Classification and Ki-67 Proliferative Index. Ophthalmic Plastic and Reconstructive Surgery, 2018, 34, 143-150.	0.4	14
224	Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis. Brain Pathology, 2018, 28, 466-474.	2.1	46
225	WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary <scp>CNS</scp> tumours. Neuropathology and Applied Neurobiology, 2018, 44, 163-171.	1.8	47

#	Article	IF	Citations
226	Near-infrared fluorescent image-guided surgery for intracranial meningioma. Journal of Neurosurgery, 2018, 128, 380-390.	0.9	62
227	Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology, 2018, 299, 299-307.	2.0	31
228	Do craniopharyngioma molecular signatures correlate with clinical characteristics?. Journal of Neurosurgery, 2018, 128, 1473-1478.	0.9	20
229	Clinicopathological and molecular characteristics of pediatric meningiomas. Neuropathology, 2018, 38, 22-33.	0.7	18
230	Voxel-based lesion mapping of meningioma: a comprehensive lesion location mapping of 260 lesions. Journal of Neurosurgery, 2018, 128, 1707-1712.	0.9	9
231	Cranial Base Meningiomas. World Neurosurgery, 2018, 109, 258-262.	0.7	11
232	The Relevance of Simpson Grade Resections in Modern Neurosurgical Treatment of World Health Organization Grade I, II, and III Meningiomas. World Neurosurgery, 2018, 109, e588-e593.	0.7	37
233	Meningiomas. , 2018, , 259-298.		12
234	Atypical meningioma: progression-free survival in 161 cases treated at our institution with surgery versus surgery and radiotherapy. Journal of Neuro-Oncology, 2018, 136, 147-154.	1.4	40
235	Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Modern Pathology, 2018, 31, 660-673.	2.9	76
236	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. JCO Precision Oncology, 2018, 2018, 1-12.	1.5	35
237	Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 158-167.	1.8	5
238	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 148-157.	1.8	2
239	New molecular targets in meningiomas: the present and the future. Current Opinion in Neurology, 2018, 31, 740-746.	1.8	13
240	Recurrent Genomic Alterations in Soft Tissue Perineuriomas. American Journal of Surgical Pathology, 2018, 42, 1708-1714.	2.1	25
241	Management of meningioma. Presse Medicale, 2018, 47, e245-e252.	0.8	29
242	Analysis of point mutations and copy number variation in Grade II and III meningioma. Experimental and Molecular Pathology, 2018, 105, 328-333.	0.9	18
243	Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. Medical Sciences (Basel, Switzerland), 2018, 6, 85.	1.3	9

#	Article	IF	Citations
244	Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas. International Journal of Molecular Sciences, 2018, 19, 3353.	1.8	25
245	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. Acta Neuropathologica, 2018, 136, 975-978.	3.9	11
246	An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Scientific Reports, 2018, 8, 13537.	1.6	49
247	Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms. World Neurosurgery, 2018, 119, 366-373.	0.7	45
248	Genetic Alterations of TRAF Proteins in Human Cancers. Frontiers in Immunology, 2018, 9, 2111.	2.2	67
249	Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation. Oncogene, 2018, 37, 4955-4963.	2.6	29
250	Radiotherapy of meningioma: a treatment in need of radiobiological research. International Journal of Radiation Biology, 2018, 94, 621-627.	1.0	11
251	Atypical Meningioma: An Evolving Landscape and Moving Target. International Journal of Radiation Oncology Biology Physics, 2018, 101, 499-502.	0.4	1
252	Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. Journal of Neuro-Oncology, 2018, 139, 469-478.	1.4	18
253	Clinical potential of meningioma genomic insights: a practical review for neurosurgeons. Neurosurgical Focus, 2018, 44, E10.	1.0	39
254	Predictors of early progression of surgically treated atypical meningiomas. Acta Neurochirurgica, 2018, 160, 1813-1822.	0.9	42
255	De Novo Missense Variants in TRAF7 Cause Developmental Delay, Congenital Anomalies, and Dysmorphic Features. American Journal of Human Genetics, 2018, 103, 154-162.	2.6	56
256	Benign Intracranial Tumors. Neurologic Clinics, 2018, 36, 501-516.	0.8	11
257	Letter: Role of Tyrosine Kinase Inhibitors in Recurrent Meningiomas: Controversies and Promises. Neurosurgery, 2018, 82, E181-E183.	0.6	1
258	Role of Macrophages in Brain Tumor Growth and Progression. International Journal of Molecular Sciences, 2018, 19, 1005.	1.8	94
259	Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. Cancers, 2018, 10, 90.	1.7	34
260	Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS ONE, 2018, 13, e0197350.	1.1	17
261	NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. International Journal of Molecular Sciences, 2018, 19, 988.	1.8	73

#	Article	IF	Citations
263	TERT Alterations in Progressive Treatment-Resistant Meningiomas. Neurosurgery, 2018, 65, 66-68.	0.6	8
264	Progesterone Receptor Is Responsible for Benign Biology of Skull Base Meningioma. World Neurosurgery, 2018, 118, e918-e924.	0.7	17
265	In situ characterization of stem cells-like biomarkers in meningiomas. Cancer Cell International, 2018, 18, 77.	1.8	15
266	An overview of meningiomas. Future Oncology, 2018, 14, 2161-2177.	1.1	300
267	Emerging Medical Treatments for Meningioma in the Molecular Era. Biomedicines, 2018, 6, 86.	1.4	42
268	Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease. Neurosurgery, 2018, 83, 1107-1118.	0.6	50
269	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathologica, 2018, 136, 779-792.	3.9	66
270	Identification of key genes and pathways in meningioma by bioinformatics analysis. Oncology Letters, 2018, 15, 8245-8252.	0.8	10
272	Extra-axial Tumors. , 2019, , 1115-1150.		1
273	Radiomics approach for prediction of recurrence in skull base meningiomas. Neuroradiology, 2019, 61, 1355-1364.	1.1	46
274	Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment. Neuro-Oncology Advances, 2019, 1, vdz003.	0.4	12
275	Chromothripsis in an Early Recurrent Chordoid Meningioma. World Neurosurgery, 2019, 130, 380-385.	0.7	7
276	ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of Î²TrCP. Nature Communications, 2019, 10, 3304.	5.8	35
277	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	0.6	49
278	Identification of shared genomic aberrations between angiomatous and microcystic meningiomas. Neuro-Oncology Advances, 2019, 1, vdz028.	0.4	1
279	Challenges and opportunities in meningiomas: recommendations from the International Consortium on Meningiomas. Neuro-Oncology, 2019, 21, i2-i3.	0.6	7
280	Molecular foundations of primary spinal tumorsâ€"implications for surgical management. Annals of Translational Medicine, 2019, 7, 222-222.	0.7	10
281	Protein Kinase A Distribution in Meningioma. Cancers, 2019, 11, 1686.	1.7	3

#	Article	IF	Citations
282	Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation. Frontiers in Oncology, 2019, 9, 1031.	1.3	14
283	The Role of Merlin/NF2 Loss in Meningioma Biology. Cancers, 2019, 11, 1633.	1.7	44
284	Highlights of the inaugural ten â€“ the launch of Neuro-Oncology Advances. Neuro-Oncology Advances, 2019, 1, vdz016.	0.4	0
285	Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine, 2019, 40, 77-91.	2.7	54
286	Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21715-21726.	3.3	122
287	Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Acta Neuropathologica Communications, 2019, 7, 140.	2.4	26
288	WHO grade of intracranial meningiomas differs with respect to patientâ€™s age, location, tumor size and peritumoral edema. Journal of Neuro-Oncology, 2019, 145, 277-286.	1.4	34
289	Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, 562-567.	0.4	18
290	Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. Journal of Neuro-Oncology, 2019, 142, 211-221.	1.4	106
291	Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology, 2019, 21, i18-i31.	0.6	102
292	Whole exome sequencing of multiple meningiomas with varying histopathological presentation in one patient revealed distinctive somatic mutation burden and independent clonal origins . Cancer Management and Research, 2019, Volume 11, 4085-4095.	0.9	11
293	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	0.6	184
294	Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas. Journal of Neuro-Oncology, 2019, 144, 11-20.	1.4	18
295	Meningiomas and Meningeal Tumors. , 2019, , 185-216.		0
296	Molecular pathology of tumors of the central nervous system. Annals of Oncology, 2019, 30, 1265-1278.	0.6	129
297	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathologica, 2019, 138, 295-308.	3.9	74
298	Transcriptome signatures associated with meningioma progression. Acta Neuropathologica Communications, 2019, 7, 67.	2.4	36
299	Multimodality Therapy of Patients with Refractory Meningiomas. Current Treatment Options in Oncology, 2019, 20, 50.	1.3	3

#	Article	IF	Citations
300	Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma. Case Reports in Oncology, 2019, 12, 126-130.	0.3	6
301	Proteomic analysis of meningiomas reveals clinically distinct molecular patterns. Neuro-Oncology, 2019, 21, 1028-1038.	0.6	42
302	Identification of KIF11 As a Novel Target in Meningioma. Cancers, 2019, 11, 545.	1.7	31
303	Extra-axial Tumors. , 2019, , 1-37.		0
304	Systemic and local immunosuppression in patients with high-grade meningiomas. Cancer Immunology, Immunotherapy, 2019, 68, 999-1009.	2.0	28
305	Fertility treatment is associated with multiple meningiomas and younger age at diagnosis. Journal of Neuro-Oncology, 2019, 143, 137-144.	1.4	12
306	Basics of Brain Tumor Biology for Clinicians. , 2019, , 7-19.		0
307	Prediction of Recurrence in Parasagittal and Parafalcine Meningiomas: Added Value of Diffusion-Weighted Magnetic Resonance Imaging. World Neurosurgery, 2019, 124, e470-e479.	0.7	10
308	Risk of Developing Postoperative Deficits Based on Tumor Location after Surgical Resection of an Intracranial Meningioma. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, 059-066.	0.4	13
309	A Brain Inspired View of Life: The Scientific, Social and Cultural Implications of Interconnectivity and Complexity. , 2019, , .		7
310	Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Modern Pathology, 2019, 32, 88-99.	2.9	76
311	3 Meningioma(s)pathology ofInside the Pathology. , 2019, , .		0
312	4 Meningioma(s)exogenous factors affectingExogenous factors, affecting meningiomaExogenous Factors Affecting Meningiomas. , 2019, , .		0
313	18 Skull base meningiomasrecurrentRecurrent skull base meningiomasManagement of Recurrent Skull Base Meningiomas. , 2019, , .		0
314	Meningiomas Display a Specific Immunoexpression Pattern in a Rostrocaudal Gradient: An Analysis of 366 Patients. World Neurosurgery, 2019, 123, e520-e535.	0.7	16
315	Molecular alterations in meningiomas: Literature review. Clinical Neurology and Neurosurgery, 2019, 176, 89-96.	0.6	28
316	Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy. Journal of Neuro-Oncology, 2019, 141, 103-109.	1.4	8
317	Agricultural Economics as a Poster Child of Applied Economics: Big Data & Big Issues¹. American Journal of Agricultural Economics, 2019, 101, 353-364.	2.4	18

#	Article	IF	Citations
318	Molecular and translational advances in meningiomas. Neuro-Oncology, 2019, 21, i4-i17.	0.6	92
319	Genetics of anophthalmia and microphthalmia. PartÂ2: Syndromes associated with anophthalmiaâ€“microphthalmia. Human Genetics, 2019, 138, 831-846.	1.8	47
320	MAB21L1 loss of function causes a syndromic neurodevelopmental disorder with distinctivecerebellar,ocular, craniofacial andgenital features (COFG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 65	1.3	25
321	Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur. Human Pathology, 2019, 84, 105-114.	1.1	8
322	Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. OncoImmunology, 2019, 8, e1512943.	2.1	31
323	Genomic profiling of anaplastic meningioma identifies recurrent genetic alterations with relevance to lowerâ€grade meningioma. Neuropathology and Applied Neurobiology, 2019, 45, 179-182.	1.8	5
324	Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. Journal of Neurosurgery, 2018, 130, 1-8.	0.9	54
325	An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathologica, 2020, 139, 643-665.	3.9	102
326	Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma. World Neurosurgery, 2020, 135, e12-e18.	0.7	12
327	Molecular characterization of localized pleural mesothelioma. Modern Pathology, 2020, 33, 271-280.	2.9	22
328	How should we manage incidental meningiomas?. Neuro-Oncology, 2020, 22, 173-174.	0.6	3
329	TRAF7 enhances ubiquitin-degradation of KLF4 to promote hepatocellular carcinoma progression. Cancer Letters, 2020, 469, 380-389.	3.2	24
330	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	3.9	45
331	Cancer of the Central Nervous System. , 2020, , 906-967.e12.		9
332	Advances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous System. Advances in Anatomic Pathology, 2020, 27, 206-219.	2.4	7
333	CaSpER identifies and visualizes CNV events by integrative analysis of single-cell or bulk RNA-sequencing data. Nature Communications, 2020, 11, 89.	5.8	96
334	Comprehending Meningioma Signaling Cascades Using Multipronged Proteomics Approaches & Targeted Validation of Potential Markers. Frontiers in Oncology, 2020, 10, 1600.	1.3	10
335	Molecular Mechanism and Approach in Progression of Meningioma. Frontiers in Oncology, 2020, 10, 538845.	1.3	8

#	Article	IF	Citations
336	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathologica Communications, 2020, 8, 171.	2.4	58
337	Molecular alterations in meningioma: prognostic and therapeutic perspectives. Current Opinion in Oncology, 2020, 32, 613-622.	1.1	51
338	Gene Expression Signatures Identify Biologically Homogenous Subgroups of Grade 2 Meningiomas. Frontiers in Oncology, 2020, 10, 541928.	1.3	4
339	Roles of TRAFs in Ischemia-Reperfusion Injury. Frontiers in Cell and Developmental Biology, 2020, 8, 586487.	1.8	1
340	Meningioma: A Review of Clinicopathological and Molecular Aspects. Frontiers in Oncology, 2020, 10, 579599.	1.3	66
341	Meningioma cells express primary cilia but do not transduce ciliary Hedgehog signals. Acta Neuropathologica Communications, 2020, 8, 114.	2.4	8
342	Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas. Scientific Reports, 2020, 10, 12563.	1.6	16
343	Natural history of intracranial meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 169, 205-227.	1.0	4
344	Characterization and comparison of genomic profiles between primary cancer cell lines and parent atypical meningioma tumors. Cancer Cell International, 2020, 20, 345.	1.8	3
345	A Practical Overview on the Molecular Biology of Meningioma. Current Neurology and Neuroscience Reports, 2020, 20, 62.	2.0	17
346	A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection. Neurosurgery, 2021, 88, 202-210.	0.6	19
347	Is DNA Methylation a Ray of Sunshine in Predicting Meningioma Prognosis?. Frontiers in Oncology, 2020, 10, 1323.	1.3	9
348	Basis for Immunotherapy for Treatment of Meningiomas. Frontiers in Neurology, 2020, 11, 945.	1.1	27
349	Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nature Communications, 2020, 11, 4803.	5.8	56
350	Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. Translational Oncology, 2020, 13, 100852.	1.7	4
351	Identification of novel fusion transcripts in meningioma. Journal of Neuro-Oncology, 2020, 149, 219-230.	1.4	6
352	Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression. Scientific Reports, 2020, 10, 14115.	1.6	20
353	GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma. EBioMedicine, 2020, 59, 102941.	2.7	17

#	Article	IF	Citations
354	A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base. Chinese Clinical Oncology, 2020, 9, 75-75.	0.4	9
355	Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management. Frontiers in Oncology, 2020, 10, 565582.	1.3	39
356	Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma. Cancers, 2020, 12, 3270.	1.7	8
357	Multiple Whole Chromosomal Gains Define Angiomatous Meningiomas and Are Absent From the Tumor Vasculature. Journal of Neuropathology and Experimental Neurology, 2020, 79, 618-625.	0.9	4
358	Phenotypic spectrum and transcriptomic profile associated with germline variants in TRAF7. Genetics in Medicine, 2020, 22, 1215-1226.	1.1	22
359	An Aggressive Extension of Dumbbell-Type Pediatric Skull Base Meningioma: A Case Report with Review of the Literature. World Neurosurgery, 2020, 139, 535-547.	0.7	4
360	Heme Oxygenase-1 in Central Nervous System Malignancies. Journal of Clinical Medicine, 2020, 9, 1562.	1.0	23
361	Olfactory groove and planum meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 170, 3-12.	1.0	7
362	Carotid artery occlusion and revascularization in the management of meningioma. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 170, 209-216.	1.0	4
363	Total DNA methylation as a biomarker of DNA damage and tumor malignancy in intracranial meningiomas. BMC Cancer, 2020, 20, 509.	1.1	10
364	Landscape of immune cell gene expression is unique in predominantly WHO grade 1 skull base meningiomas when compared to convexity. Scientific Reports, 2020, 10, 9065.	1.6	10
365	Parasellar Meningiomas. Neuroendocrinology, 2020, 110, 780-796.	1.2	14
366	The Hippo Pathway as a Driver of Select Human Cancers. Trends in Cancer, 2020, 6, 781-796.	3.8	39
367	The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis. Oncogene, 2020, 39, 5267-5281.	2.6	53
368	DNA methylation profiling demonstrates superior diagnostic classification to RNA-sequencing in a case of metastatic meningioma. Acta Neuropathologica Communications, 2020, 8, 82.	2.4	10
369	Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma. Cancers, 2020, 12, 1478.	1.7	21
370	Association of Race with Survival in Intracranial World Health Organization Grade II and III Meningioma in the United States: Systematic Literature Review. World Neurosurgery, 2020, 138, e361-e369.	0.7	5
371	Diagnosis and Treatment of Parasellar Lesions. Neuroendocrinology, 2020, 110, 728-739.	1.2	19

#	Article	IF	Citations
372	Epidemiology of meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 169, 3-15.	1.0	17
373	Atypical meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 170, 233-244.	1.0	10
374	High Copy-Number Variation Burdens in Cranial Meningiomas From Patients With Diverse Clinical Phenotypes Characterized by Hot Genomic Structure Changes. Frontiers in Oncology, 2020, 10, 1382.	1.3	7
375	Current decision-making in meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 169, 229-252.	1.0	4
376	Molecular genetics of meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 169, 101-119.	1.0	5
377	Medical management of meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 170, 291-302.	1.0	3
378	Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. Current Oncology Reports, 2020, 22, 84.	1.8	17
379	Mutation Status and Epithelial Differentiation Stratify Recurrence Risk in Chordoid Meningiomaâ€”A Multicenter Study with High Prognostic Relevance. Cancers, 2020, 12, 225.	1.7	14
380	Stromal Hedgehog pathway activation by IHH suppresses lung adenocarcinoma growth and metastasis by limiting reactive oxygen species. Oncogene, 2020, 39, 3258-3275.	2.6	16
381	A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours. International Journal of Molecular Sciences, 2020, 21, 1273.	1.8	10
382	The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations. Neuro-Oncology Advances, 2020, 2, vdz055.	0.4	9
383	Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Clinical Cancer Research, 2020, 26, 552-557.	3.2	87
384	Recent Advances in Meningioma Immunogenetics. Frontiers in Oncology, 2019, 9, 1472.	1.3	42
385	Multiple Pulmonary and Pleural Metastases in Recurrent Intracranial Meningioma with Genetic Changes: Case Report and Review of the Literature. World Neurosurgery, 2020, 136, 337-340.	0.7	4
386	Hemangiopericytomas: Spatial Intracranial Location in a Voxelâ€Based Mapping Study. Journal of Neuroimaging, 2020, 30, 370-377.	1.0	1
387	KLF4K409Qâ€“mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment. Acta Neuropathologica Communications, 2020, 8, 41.	2.4	25
388	Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker. Clinical Cancer Research, 2020, 26, 193-205.	3.2	6
389	Novel histopathological classification of meningiomas based on dural invasion. Journal of Clinical Pathology, 2021, 74, 238-243.	1.0	4

#	Article	IF	Citations
390	NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. Cancer Immunology, Immunotherapy, 2021, 70, 169-176.	2.0	12
391	Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions. Gut, 2021, 70, 928-939.	6.1	48
392	Associations of meningioma molecular subgroup and tumor recurrence. Neuro-Oncology, 2021, 23, 783-794.	0.6	83
393	Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis. Acta Neurochirurgica, 2021, 163, 57-66.	0.9	19
394	The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges. Oncogene, 2021, 40, 875-884.	2.6	13
395	Regulation of Hedgehog Signaling by miRNAs and Nanoformulations: A Possible Therapeutic Solution for Colorectal Cancer. Frontiers in Oncology, 2020, 10, 607607.	1.3	7
396	Alteration of FOXM1 expression and macrophage polarization in refractory meningiomas during long-term follow-up. Translational Cancer Research, 2021, 10, 553-566.	0.4	4
397	Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center. Neuro-Oncology Advances, 2021, 3, vdab094.	0.4	5
398	Tumours of Central Nervous System. , 2021, , 71-91.		0
399	Meningeome. Springer Reference Medizin, 2021, , 1-13.	0.0	1
400	Tumors of the Central Nervous System. , 2021, , 121-145.		0
401	Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells. Bioengineered, 2021, 12, 755-762.	1.4	11
402	Double Meningioma: A Case of Two Fibrous Meningiomas Coexisting Isolatedly in Meningothelial Meningioma. NMC Case Report Journal, 2021, 8, 215-220.	0.2	0
403	Pathology and Molecular Pathology of Meningioma. , 2021, , 67-77.		0
404	Sporadic multiple meningiomas harbor distinct driver mutations. Acta Neuropathologica Communications, 2021, 9, 8.	2.4	12
405	The Expanding Role of Geometric Morphometrics in Craniofacial Surgery. Journal of Craniofacial Surgery, 2021, 32, 1104-1109.	0.3	15
406	Clinical significance of checkpoint regulator â€œProgrammed death ligand-1 (PD-L1)â€•expression in meningioma: review of the current status. Journal of Neuro-Oncology, 2021, 151, 443-449.	1.4	13
407	Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival. Cancers, 2021, 13, 903.	1.7	20

#	Article	IF	Citations
408	Meningioma: A Pathology Perspective. Neurosurgery, 2021, 89, 11-21.	0.6	9
409	Multiple meningiomas arising within the same hemisphere associated with Li-Fraumeni syndrome. , 2021, 12, 99.		1
410	Atypical meningioma: a retrospective analysis of six cases and literature review. Translational Cancer Research, 2021, 10, 1509-1518.	0.4	1
411	SWI/SNF chromatin remodeling complex alterations in meningioma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3431-3440.	1.2	15
412	Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions. Biomedicines, 2021, 9, 319.	1.4	79
413	Identifying and Regulating the Environmental Risks in the Development and Utilization of Natural Gas as a Low-Carbon Energy Source. Frontiers in Energy Research, 2021, 9, .	1.2	13
414	Sustained growth of intraosseous hormone-associated meningiomas after cessation of progestin therapy. Acta Neurochirurgica, 2021, 163, 1705-1710.	0.9	3
415	Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. Scientific Reports, 2021, 11, 6987.	1.6	23
416	Hedgehog signaling mechanism and role in cancer. Seminars in Cancer Biology, 2022, 85, 107-122.	4.3	60
417	Differences in the expression of SSTR1â€“5 in meningiomas and its therapeutic potential. Neurosurgical Review, 2021, , 1.	1.2	12
418	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology, 2021, 23, 1922-1935.	0.6	33
419	Commentary: The Ki-67 Proliferation Index as a Marker of Time to Recurrence in Intracranial Meningioma. Neurosurgery, 2021, 89, E66-E67.	0.6	0
420	Advances in Multidisciplinary Management of Skull Base Meningiomas. Cancers, 2021, 13, 2664.	1.7	10
421	TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma. Human Pathology, 2021, 111, 59-66.	1.1	9
422	Crispr/Cas-based modeling of NF2 loss in meningioma cells. Journal of Neuroscience Methods, 2021, 356, 109141.	1.3	10
424	KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Letters, 2021, 506, 1-10.	3.2	17
425	Meningiomas after cyproterone acetate exposure: Case reports in twin sisters. Therapie, 2021, 76, 255-257.	0.6	3
426	RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth. Neuro-Oncology, 2022, 24, 14-26.	0.6	17

#	Article	IF	Citations
427	Effect of adjuvant radiotherapy after subtotal resection for WHO grade I meningioma: a propensity score matching analysis of the Brain Tumor Registry of Japan. Journal of Neuro-Oncology, 2021, 153, 351-360.	1.4	11
428	Design and Synthesis of New Withaferin A Inspired Hedgehog Pathway Inhibitors. Chemistry - A European Journal, 2021, 27, 8350-8357.	1.7	5
429	Biomarkers for differentiating grade II meningiomas from grade I: a systematic review. British Journal of Neurosurgery, 2021, 35, 696-702.	0.4	7
430	Skull Base Tumors: Neuropathology and Clinical implications. Neurosurgery, 2021, 90, .	0.6	3
432	Brain Invasion in Meningiomaâ€"A Prognostic Potential Worth Exploring. Cancers, 2021, 13, 3259.	1.7	18
433	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncology, 2021, 10, CNS72.	1.2	54
434	Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. Molecular Cancer Therapeutics, 2021, 20, 1584-1591.	1.9	11
435	Sarcomatous Meningioma: Diagnostic Pitfalls and the Utility of Molecular Testing. Journal of Neuropathology and Experimental Neurology, 2021, 80, 764-768.	0.9	4
436	GAB1 overexpression identifies hedgehogâ€activated anterior skull base meningiomas. Neuropathology and Applied Neurobiology, 2021, 47, 748-755.	1.8	6
438	Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development. Cancer Research, 2021, 81, 4218-4229.	0.4	13
439	Clinical features and long-term outcomes of pediatric meningiomas. Child's Nervous System, 2021, 37, 3041-3047.	0.6	5
440	Newly established patient-derived organoid model of intracranial meningioma. Neuro-Oncology, 2021, 23, 1936-1948.	0.6	26
441	High-Throughput Mechanistic Screening of Epigenetic Compounds for the Potential Treatment of Meningiomas. Journal of Clinical Medicine, 2021, 10, 3150.	1.0	5
442	Innovations in Neuro-Oncology. World Neurosurgery, 2021, 151, 386-391.	0.7	5
443	Risk Factors for High-Grade Meningioma in Brain and Spine: Systematic Review and Meta-analysis. World Neurosurgery, 2021, 151, e718-e730.	0.7	9
444	Case Report: Blepharophimosis and Ptosis as Leading Dysmorphic Features of Rare Congenital Malformation Syndrome With Developmental Delay â€" New Cases With TRAF7 Variants. Frontiers in Medicine, 2021, 8, 708717.	1.2	4
445	Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. Journal of Neuro-Oncology, 2021, 154, 237-246.	1.4	11
446	Comprehensive proteomic analysis reveals distinct functional modules associated with skull base and supratentorial meningiomas and perturbations in collagen pathway components. Journal of Proteomics, 2021, 246, 104303.	1.2	4

#	Article	IF	Citations
447	Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis. Cell Reports, 2021, 36, 109596.	2.9	15
448	A clinically applicable integrative molecular classification of meningiomas. Nature, 2021, 597, 119-125.	13.7	180
449	Atypical Presentation of Transcranial Extension of Intracranial Meningiomas. American Journal of Dermatopathology, 2021, Publish Ahead of Print, 207-211.	0.3	1
450	Genomic Biomarkers of Meningioma: A Focused Review. International Journal of Molecular Sciences, 2021, 22, 10222.	1.8	9
451	SomaticPIK3CAMutations in Sporadic Cerebral Cavernous Malformations. New England Journal of Medicine, 2021, 385, 996-1004.	13.9	53
452	Residual Tumor Volume and Tumor Progression after Subtotal Resection and Observation of WHO Grade I Skull Base Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, e530-e536.	0.4	1
453	Clinical and genomic factors associated with seizures in meningiomas. Journal of Neurosurgery, 2021, 135, 835-844.	0.9	17
454	WHO grade III meningioma: De novo tumors show improved progression free survival as compared to secondary progressive tumors. Journal of Clinical Neuroscience, 2021, 91, 105-109.	0.8	3
455	Molecular Alterations in Meningioangiomatosis Causing Epilepsy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1043-1051.	0.9	3
456	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. Acta Neuropathologica, 2021, 142, 873-886.	3.9	12
457	A molecularly integrated grade for meningioma. Neuro-Oncology, 2022, 24, 796-808.	0.6	83
458	Clinical Characteristics and Magnetic Resonance Imagingâ€“Based Prediction of the KLF4 Mutation in Meningioma. World Neurosurgery, 2021, 154, e665-e670.	0.7	3
459	Preliminary report of patients with meningiomas exposed to Cyproterone Acetate, Nomegestrol Acetate and Chlormadinone Acetate â€“ Monocentric ongoing study on progestin related meningiomas. Clinical Neurology and Neurosurgery, 2021, 210, 106959.	0.6	5
460	Understanding Meningioma and Treatment : Treatment Strategy based on Angioarchitecture and Review of the Current Genomic Research. Japanese Journal of Neurosurgery, 2021, 30, 4-10.	0.0	0
461	Pathology of the Spinal Cord Tumors. , 2021, , 7-25.		1
462	EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncology, 2021, 23, 1821-1834.	0.6	230
463	Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 150-159.	0.9	9
464	Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis. International Journal of Molecular Sciences, 2021, 22, 690.	1.8	49

#	Article	IF	Citations
465	Combination of p53 and Ki67 as a Promising Predictor of Postoperative Recurrence of Meningioma. Anticancer Research, 2021, 41, 203-210.	0.5	5
466	Primary Central Nervous System Tumors. , 2020, , 295-325.		1
467	Causal Factors for Brain Tumor and Targeted Strategies. Springer Proceedings in Physics, 2014, , 191-204.	0.1	2
468	The Essentials of Molecular Testing in CNS Tumors: What to Order and How to Integrate Results. Current Neurology and Neuroscience Reports, 2020, 20, 23.	2.0	9
469	Molecular Advances in Central Nervous System Mesenchymal Tumors. Surgical Pathology Clinics, 2020, 13, 291-303.	0.7	2
471	Misactivation of Hedgehog signaling causes inherited and sporadic cancers. Journal of Clinical Investigation, 2019, 129, 465-475.	3.9	72
472	Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment. Histology and Histopathology, 2020, 35, 741-749.	0.5	9
473	MiR-34a-3p alters proliferation and apoptosis of meningioma cells in vitro and is directly targeting SMAD4, FRAT1 and BCL2. Aging, 2017, 9, 932-954.	1.4	35
474	Overexpression of KLF4 promotes cell senescence through microRNA-203-survivin-p21 pathway. Oncotarget, 2016, 7, 60290-60302.	0.8	28
475	Epithelial differentiation with microlumen formation in meningioma: diagnostic utility of NHERF1/EBP50 immunohistochemistry. Oncotarget, 2018, 9, 28652-28665.	0.8	11
476	Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas. Oncotarget, 2019, 10, 3506-3517.	0.8	15
477	Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies. Oncotarget, 2020, 11, 4544-4553.	0.8	10
478	Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget, 2015, 6, 1981-1994.	0.8	38
479	Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget, 2016, 7, 14551-14568.	0.8	36
480	Recent advances in cerebral cavernous malformation research. Vessel Plus, 2018, 2, 21.	0.4	54
481	Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. Journal of Neurosurgery, 2020, 133, 1345-1354.	0.9	83
482	Non-Canonical Hh Signaling in Cancerâ€"Current Understanding and Future Directions. Cancers, 2015, 7, 1684-1698.	1.7	54
483	Loss of SMARCB1/INI1 Immunoexpression in Chordoid Meningiomas. Neurology India, 2019, 67, 1492.	0.2	1

#	Article	IF	Citations
484	1p/14q co-deletion: A determinant of recurrence in histologically benign meningiomas. Indian Journal of Pathology and Microbiology, 2015, 58, 433.	0.1	5
485	Molecular characteristics of meningiomas. Journal of Pathology and Translational Medicine, 2020, 54, 45-63.	0.4	46
486	Chemotherapy and targeted therapies for meningiomas: what is the evidence?. Current Opinion in Neurology, 2021, 34, 857-867.	1.8	13
487	Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization. Acta Neurochirurgica, 2022, 164, 255-263.	0.9	3
488	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. Diagnostics, 2021, 11, 1852.	1.3	11
489	Case Report: Identification of a Novel GNAS Mutation and 1p/22q Co-Deletion in a Patient With Multiple Recurrent Meningiomas Sensitive to Sunitinib. Frontiers in Oncology, 2021, 11, 737523.	1.3	3
490	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	0.8	93
491	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer, 2022, 128, 47-58.	2.0	132
492	Comprehensive overview of extracellular vesicle proteomics in meningioma: future strategy. Molecular Biology Reports, 2021, 48, 8061-8074.	1.0	1
493	Nuevas perspectivas moleculares para el tratamiento de los meningiomas anaplÃ¡sicos recurrentes : a propÃ³sito de un caso.. Revista Colombiana De Hematologìa Y Oncologìa, 2013, 2, 40-44.	0.0	0
500	Genomic Applications in Brain Tumors. , 2019, , 289-308.		0
503	Stereotactic Radiosurgery for Meningioma. , 2019, , 123-129.		0
509	TERT Alterations Predict Tumor Progression in De Novo High-Grade Meningiomas Following Adjuvant Radiotherapy. Frontiers in Oncology, 2021, 11, 747592.	1.3	4
510	Personalized Management of Cancers of Various Organs/Systems. , 2021, , 509-602.		0
512	The Genomic Landscape of Meningiomas. , 2020, , 35-55.		1
513	Emerging Meningioma Therapies I: Precision Medicine, Targeted Therapies, and Mutation-Specific Approaches. , 2020, , 217-226.		0
514	Genomic Analysis and Gene-based Medicine for Benign Brain Tumors. Japanese Journal of Neurosurgery, 2020, 29, 536-542.	0.0	0
515	Surgical Considerations for Newly Diagnosed Meningiomas. , 2020, , 75-96.		1

#	Article	IF	Citations
516	Low Grade Tumor Recurrence and Management of More Aggressive Meningiomas. , 2020, , 147-159.		0
517	The Loss of 1p as a Reliable Marker of Progression in a Child with Aggressive Meningioma: A 16-Year Follow-Up Case Report. Pediatric Neurosurgery, 2020, 55, 418-425.	0.4	1
518	An Overview of Meningiomas. , 2020, , 3-10.		1
519	Meningioma Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 33-48.	0.8	5
521	The biological and diagnostic roles of MicroRNAs in meningiomas. Reviews in the Neurosciences, 2020, 31, 771-778.	1.4	13
523	Overlapping variants in the blood, tissues and cell lines for patients with intracranial meningiomas are predominant in stem cell-related genes. Heliyon, 2020, 6, e05632.	1.4	4
524	Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes. Discovery Medicine, 2014, 18, 301-311.	0.5	20
525	Imaging Advances in Stereotactic Radiosurgery. Missouri Medicine, 2015, 112, 373-8.	0.3	0
526	Expression of hydrogen sulfide synthases and Hh signaling pathway components correlate with the clinicopathological characteristics of papillary thyroid cancer patients. International Journal of Clinical and Experimental Pathology, 2018, 11, 1818-1824.	0.5	4
527	Biology and Treatment of Meningiomas. Hematology/Oncology Clinics of North America, 2022, 36, 133-146.	0.9	3
528	Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo. Cancers, 2021, 13, 5898.	1.7	7
529	AKT1^{E17K}â€mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363. Neuropathology and Applied Neurobiology, 2022, 48, e12780.	1.8	8
530	The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications. Journal of Neuro-Oncology, 2022, 156, 205-214.	1.4	12
531	Consensus core clinical data elements for meningiomas (v2021.1). Neuro-Oncology, 2022, 24, 683-693.	0.6	7
532	Tumor-Derived Cell Culture Model for the Investigation of Meningioma Biology. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1117-1124.	0.9	3
534	Immunotherapy for Neuro-oncology. Advances in Experimental Medicine and Biology, 2021, 1342, 233-258.	0.8	4
535	Histogram analysis of tensor-valued diffusion MRI in meningiomas: Relation to consistency, histological grade and type. NeuroImage: Clinical, 2022, 33, 102912.	1.4	11
536	Genomic sequencing of a pregnancy associated symptomatic meningioma of the diaphragma sellae: a case report. British Journal of Neurosurgery, 2022, , 1-5.	0.4	0

#	Article	IF	Citations
537	Trabectedin for recurrent WHO grade 2 or 3 meningiomasâ€"paving the road for new opportunities. Neuro-Oncology, 2022, , .	0.6	0
538	Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series. Current Oncology, 2022, 29, 178-185.	0.9	3
539	Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Science Advances, 2022, 8, eabm6247.	4.7	33
540	A new ampliconâ€based gene panel for next generation sequencing characterization of meningiomas. Brain Pathology, 2022, 32, e13046.	2.1	7
541	Introduction to the miniâ€symposium â€œmolecular neuropathology of meningiomaâ€. Brain Pathology, 2022, 32, e13055.	2.1	2
542	Prognostic impact of genetic alterations and methylation classes in meningioma. Brain Pathology, 2022, 32, e12970.	2.1	27
543	Identification and Management of Aggressive Meningiomas. Frontiers in Oncology, 2022, 12, 851758.	1.3	10
544	Comparison of Active Surveillance to Stereotactic Radiosurgery for the Management of Patients with an Incidental Frontobasal Meningiomaâ€"A Sub-Analysis of the IMPASSE Study. Cancers, 2022, 14, 1300.	1.7	4
545	Avenaciolide Induces Apoptosis in Human Malignant Meningioma Cells through the Production of Reactive Oxygen Species. Biological and Pharmaceutical Bulletin, 2022, 45, 517-521.	0.6	2
546	High Grade Meningiomas: Current Therapy Based on Tumor Biology. , 0, , .		1
547	Ki67 Index Is the Most Powerful Factor for Predicting the Recurrence in Atypical Meningioma : Retrospective Analysis of 99 Patients in Two Institutes. Journal of Korean Neurosurgical Society, 2022, 65, 558-571.	0.5	4
548	SPHENOID WING MENINGIOMAS WITH SECONDARY CAVERNOUS SINUS INVASION: SURGICAL RESULTS AND ALGORITHM FOR TREATMENT AT A SINGLE BRAZILIAN CENTER. World Neurosurgery, 2022, , .	0.7	1
549	Meningeal Mass Lesions. , 0, , 40-63.		0
568	Regrowth factors of WHO grade I skull base meningiomas following incomplete resection. Journal of Neurosurgery, 2022, 137, 1656-1665.	0.9	2
569	Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas. Frontiers in Oncology, 2021, 11, 740782.	1.3	5
570	Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand?. Cancers, 2022, 14, 2256.	1.7	9
571	Transcriptomic Profiling Revealed Lnc-GOLGA6A-1 as a Novel Prognostic Biomarker of Meningioma Recurrence. Neurosurgery, 2022, 91, 360-369.	0.6	6
572	Extent of Resection Research in Skull Base Neurosurgery: Previous Studies and Future Directions. World Neurosurgery, 2022, 161, 396-404.	0.7	1

#	Article	IF	Citations
573	Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nature Genetics, 2022, 54, 649-659.	9.4	93
574	Primary Benign Tumors of the Spinal Canal. World Neurosurgery, 2022, 164, 178-198.	0.7	8
576	Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. Acta Neuropathologica Communications, 2022, 10, 76.	2.4	10
577	Genomic profiling of sporadic multiple meningiomas. BMC Medical Genomics, 2022, 15, 112.	0.7	3
578	Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype. Journal of Neuro-Oncology, 2023, 161, 193-202.	1.4	2
579	Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature. Frontiers in Oncology, 0, 12, .	1.3	1
580	TRAF7 somatic mosaicism in a patient with bilateral optic nerve sheath meningiomas: illustrative case. Journal of Neurosurgery Case Lessons, 2022, 3, .	0.1	1
581	Epigenetic Dysregulation in Meningiomas. Neuro-Oncology Advances, 0, , .	0.4	0
582	Clinicopathologic Characteristics of Grade 2/3 Meningiomas: A Perspective on the Role of Next-Generation Sequencing. Frontiers in Oncology, 0, 12, .	1.3	3
583	SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma. Nature Genetics, 2022, 54, 861-873.	9.4	16
584	New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies. Journal of Dental Research, 0, , 002203452211007.	2.5	4
585	NF2 Alteration/22q Loss Is Associated with Recurrence in WHO Grade 1 Sphenoid Wing Meningiomas. Cancers, 2022, 14, 3183.	1.7	0
586	Bone Invasive Meningioma: Recent Advances and Therapeutic Perspectives. Frontiers in Oncology, 0, 12, .	1.3	4
587	Landscape of genetic variants in sporadic meningiomas captured with clinical genomics. Acta Neurochirurgica, 2022, 164, 2491-2503.	0.9	2
588	Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2 mutant meningiomas in mice. Genes and Development, 2022, 36, 857-870.	2.7	14
589	Molecular determinants of outcomes in meningiomas. Frontiers in Oncology, 0, 12, .	1.3	4
590	Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer. Cells, 2022, 11, 2523.	1.8	6
591	Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord. Acta Neuropathologica, 2022, 144, 1053-1055.	3.9	8

#	Article	IF	Citations
592	Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data. Neurosurgical Review, 0, , .	1.2	4
593	Metastatic grade 1 meningioma lacking genetic abnormalities commonly associated with bad prognosis. Pathology Research and Practice, 2022, 238, 154089.	1.0	0
594	Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas. Acta Neuropathologica, 2022, 144, 799-802.	3.9	2
595	Mutated KLF4(K409Q) in meningioma binds STRs and activates FGF3 gene expression. IScience, 2022, 25, 104839.	1.9	2
596	Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib. Cancers, 2022, 14, 4448.	1.7	4
597	The Role of TRAF7 in Tumorigenesis. World Journal of Cancer Research, 2022, 12, 188-198.	0.1	0
599	Matched Paired Primary and Recurrent Meningiomas Points to Cell-Death Program Contributions to Genomic and Epigenomic Instability along Tumor Progression. Cancers, 2022, 14, 4008.	1.7	0
600	Genetic and epigenetic profiling identifies two distinct classes of spinal meningiomas. Acta Neuropathologica, 2022, 144, 1057-1059.	3.9	3
601	Molecular landscapes of longitudinal <scp>NF2</scp>/22q and <scp>nonâ€NF2</scp>/22q meningiomas show different life histories. Brain Pathology, 2023, 33, .	2.1	2
603	Intracranial meningiomas: clinical, intrascopic and pathomorphological causes of recurrence (literature review). Siberian Journal of Oncology, 2022, 21, 110-123.	0.1	3
604	Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Cell Genomics, 2022, 2, 100179.	3.0	74
605	Application of MRI-Based Radiomics in Preoperative Prediction of NF2 Alteration in Intracranial Meningiomas. Frontiers in Oncology, 0, 12, .	1.3	2
606	Analysis of clinicopathological features and NAB2-STAT6 fusion variants of meningeal solitary fibrous tumor with ectopic salivary gland components in the cerebellopontine angle. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 913-923.	1.4	3
607	Molecular diagnosis and treatment of meningiomas: an expert consensus (2022). Chinese Medical Journal, 2022, 135, 1894-1912.	0.9	5
608	Emerging systemic treatment options in meningioma. Journal of Neuro-Oncology, 0, , .	1.4	14
609	Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. Journal of Clinical Oncology, 2023, 41, 618-628.	0.8	27
610	Cytogenetic and Molecular Characterization of IDH-Wildtype Glioblastomas and Grade 4 IDH-Mutant Astrocytomas with Unusual Histology. Journal of Neuropathology and Experimental Neurology, 2022, 81, 996-1001.	0.9	0
611	Radiotherapy for meningiomas. Journal of Neuro-Oncology, 2022, 160, 505-515.	1.4	10

#	Article	IF	Citations
613	Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma. Biomedicine and Pharmacotherapy, 2022, 155, 113843.	2.5	5
614	Management of High-Grade Meningioma: Present, Past and Promising Future. , 0, , .		0
615	Surgical complications and recurrence factors for asymptomatic meningiomas: a single-center retrospective study. Acta Neurochirurgica, 2023, 165, 1345-1353.	0.9	2
616	TRAF7-mutated Fibromyxoid Spindle Cell Tumors Are Associated With an Aggressive Clinical Course and Harbor an Undifferentiated Sarcoma Methylation Signature. American Journal of Surgical Pathology, 2023, 47, 270-277.	2.1	2
617	Clinical Management of Supratentorial Non-Skull Base Meningiomas. Cancers, 2022, 14, 5887.	1.7	2
618	Malignant meningioma. Apmis, 2022, 130, 1-58.	0.9	1
619	Importancia pronÃ³stica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado. Biomedica, 2022, 42, 574-590.	0.3	0
620	XCVATR: detection and characterization of variant impact on the Embeddings of single -cell and bulk RNA-sequencing samples. BMC Genomics, 2022, 23, .	1.2	1
621	Association between tumor mutations and meningioma recurrence in Grade I/II disease. Oncoscience, 2022, 9, 70-81.	0.9	1
622	Biology and Genetics of Vestibular Schwannomas in Tumors of the Cerebellopontine Angle. , 2022, , 121-132.		0
623	Genomic markers of recurrence risk in atypical meningioma following gross total resection. Neuro-Oncology Advances, 2023, 5, .	0.4	3
624	Recent advances in the molecular prognostication of meningiomas. Frontiers in Oncology, 0, 12, .	1.3	1
625	Signaling pathways in brain tumors and therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	13
626	A current review of spinal meningiomas: epidemiology, clinical presentation and management. Journal of Neuro-Oncology, 2023, 161, 395-404.	1.4	2
627	The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review. Cancers, 2023, 15, 483.	1.7	7
628	Metastatic Meningioma: A Systematic Review of Incidence and Risk Factors. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2023, , 101720.	0.2	1
629	GAB1 as a Marker of Recurrence in Anterior Skull Base Meningioma. Neurosurgery, 2023, 92, 391-397.	0.6	1
630	Brain Invasion and Trends in Molecular Research on Meningioma. Brain Tumor Research and Treatment, 2023, 11, 47.	0.4	2

#	Article	IF	Citations
631	WHO grade and pathological markers of meningiomas: Clinical and prognostic role. Pathology Research and Practice, 2023, 243, 154340.	1.0	1
632	Association between preoperative hematologic markers and aggressive behavior in meningiomas. Clinical Neurology and Neurosurgery, 2023, 226, 107629.	0.6	2
633	Surgical strategies for intracranial meningioma in the molecular era. Journal of Neuro-Oncology, 2023, 162, 253-265.	1.4	5
634	Long-read sequencing reveals the effect of follicle-stimulating hormone on the mRNA profile of chicken granulosa cells from prehierarchical follicles. Poultry Science, 2023, 102, 102600.	1.5	3
636	Molecular Characterization of Testicular Mesothelioma and the Role of Asbestos as a Causative Factor. Archives of Pathology and Laboratory Medicine, 2023, 147, 1446-1450.	1.2	2
637	Molecular classification and grading of meningioma. Journal of Neuro-Oncology, 2023, 161, 373-381.	1.4	4
638	Inhibition of the epigenetically activated miR-483-5p/IGF-2 pathway results in rapid loss of meningioma tumor cell viability. Journal of Neuro-Oncology, 2023, 162, 109-118.	1.4	1
639	The multiomic landscape of meningiomas: a review and update. Journal of Neuro-Oncology, 2023, 161, 405-414.	1.4	3
640	Specific gene expression signatures of low grade meningiomas. Frontiers in Oncology, 0, 13, .	1.3	1
641	Modeling nervous system tumors with human stem cells and organoids. Cell Regeneration, 2023, 12, .	1.1	3
642	Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression. BMC Cancer, 2023, 23, .	1.1	0
643	Advances and trends in meningioma research over the last decade: A scientometric and visual analysis. Frontiers in Oncology, 0, 13, .	1.3	0
644	Thyroid cancer, neuroendocrine tumor, adrenal adenoma and other tumors in a patient with a germline PMS1 mutation. Journal of the Endocrine Society, 0, , .	0.1	1
645	DNA methylation provides diagnostic value for meningioma recurrence in clinical practice. Acta Neurochirurgica, 2023, 165, 1323-1331.	0.9	2
647	Innovative treatments for meningiomas. Revue Neurologique, 2023, 179, 449-463.	0.6	1
648	Novel Systemic Approaches for the Management of Meningiomas. Neurosurgery Clinics of North America, 2023, , .	0.8	1
649	KLF4 transcription factor in tumorigenesis. Cell Death Discovery, 2023, 9, .	2.0	15
650	Medical Management of Meningiomas. Neurosurgery Clinics of North America, 2023, , .	0.8	0

#	Article	IF	Citations
651	A Future Blood Test to Detect Cerebral Aneurysms. Cellular and Molecular Neurobiology, 2023, 43, 2697-2711.	1.7	2
652	Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	4
653	The first prospective application of AIGS real-time fluorescence PCR in precise diagnosis and treatment of meningioma: Case report. Frontiers in Neuroscience, 0, 17, .	1.4	0
654	Review of meningioma diagnosis and management. Egyptian Journal of Neurosurgery, 2023, 38, .	0.2	1
655	Uncovering the molecular landscape of meningiomas and the impact of perioperative steroids on patient survival. Acta Neurochirurgica, 0, , .	0.9	1
667	Advances in Central Nervous System Tumor Classification. Advances in Experimental Medicine and Biology, 2023, , 121-135.	0.8	0
669	Genomic Landscape of Meningiomas. Advances in Experimental Medicine and Biology, 2023, , 137-158.	0.8	0
670	Clinical Presentation and Prognosis. Advances in Experimental Medicine and Biology, 2023, , 5-20.	0.8	0
671	Paradigm Shift in the Treatment of Meningiomas. Advances in Experimental Medicine and Biology, 2023, , 1-4.	0.8	0
672	Novel Medical Therapies in Meningiomas. Advances in Experimental Medicine and Biology, 2023, , 213-223.	0.8	3
673	Immunotherapy for Meningiomas. Advances in Experimental Medicine and Biology, 2023, , 225-234.	0.8	0
674	Preclinical Models of Meningioma. Advances in Experimental Medicine and Biology, 2023, , 199-211.	0.8	0
675	Meningioma and Other Meningeal Tumors. Advances in Experimental Medicine and Biology, 2023, , 73-97.	0.8	0
678	Pathology of the Tumors of the Central Nervous System. , 2023, , 71-110.		0
689	Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes. Acta Neuropathologica, 0, , .	3.9	0
703	Benign Adult Brain Tumors and Pediatric Brain Tumors. , 2024, , 214-233.		0